title: Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
authors.affiliation: Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. tallal.younis@cdha.nshealth.ca
authors.forename: Tallal
authors.initials: T
authors.lastname: Younis
authors.forename: Chris
authors.initials: C
authors.lastname: Skedgel
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D017024:Chemotherapy, Adjuvant / Q000191:economics; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D057239:Early Termination of Clinical Trials; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab